Pati Maria Laura, Niso Mauro, Spitzer Dirk, Berardi Francesco, Contino Marialessandra, Riganti Chiara, Hawkins William G, Abate Carmen
Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, I-70125 Bari, Italy; Department of Surgery, Division of Hepatobiliary, Pancreatic, and Gastrointestinal Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, I-70125 Bari, Italy.
Eur J Med Chem. 2018 Jan 20;144:359-371. doi: 10.1016/j.ejmech.2017.12.024. Epub 2017 Dec 8.
The aggressiveness of pancreatic cancer urgently requires more efficient treatment options. Because the sigma-2 (σ) receptor was recently proposed as a promising target for pancreatic cancer therapy, we explored our previously developed multifunctional thiosemicarbazones, designed to synergistically impair cell energy levels, by targeting σ and P-gp proteins and chelating Iron. A deconstruction approach was herein applied by removing one function at a time from the potent multifunctional thiosemicarbazones 1 and 2, to investigate the contribution to cytotoxicity of each target involved. The results from in vitro (panel of pancreatic tumor cells) and in vivo experiments (C57BL/6 bearing KP02 tumor), suggest that while the multifunctional activity was not required for the antitumor activity of these thiosemicarbazones, σ-targeting appeared to allow alternative tumor cell death mechanisms, leading to potent and less toxic off-targets toxicities compared to other thiosemicarbazones devoid of σ-targeting.
胰腺癌的侵袭性迫切需要更有效的治疗方案。由于最近有人提出σ-2(σ)受体是胰腺癌治疗的一个有前景的靶点,我们研究了我们之前开发的多功能硫代氨基脲,其设计目的是通过靶向σ和P-糖蛋白以及螯合铁来协同损害细胞能量水平。本文采用解构方法,从强效多功能硫代氨基脲1和2中一次去除一种功能,以研究每个相关靶点对细胞毒性的贡献。体外实验(一组胰腺肿瘤细胞)和体内实验(携带KP02肿瘤的C57BL/6小鼠)的结果表明,虽然这些硫代氨基脲的抗肿瘤活性不需要多功能活性,但与其他不靶向σ的硫代氨基脲相比,靶向σ似乎允许通过替代的肿瘤细胞死亡机制,导致强效且毒性较低的脱靶毒性。